# US 2014/0154280 A1 · Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154280 A1
- Document ID: US20140154280A1
- Status: Published application
- Kind: A1
- Application number: 14/095,947
- Filed: 2013-12-03
- Published: 2014-06-05
- Earliest claimed: 2012-12-05
- Assignees: TheVax Genetics Vaccine Co., Ltd.
- Applicants: TheVax Genetics Vaccine Co., Ltd.
- Inventors: Wei-I CHOU; Chia-Mao Wu; Jiun-Ming Wu; Hsiu-Kang Chang
- Web page: https://patentgrep.com/patent/US20140154280A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/135: Foot- and mouth-disease virus
- A61K 39/17: Newcastle disease virus
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/29: Hepatitis virus
- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/81: Protease inhibitors
- C12N 9/1077: {Pentosyltransferases (2.4.2)}
- C12N 9/14: Hydrolases (3)
- C12Y 204/02036: NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
- C12Y 306/05002: Small monomeric GTPase (3.6.5.2)
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/6031: {Proteins}
- C07K 14/21: from Pseudomonadaceae (F)
- C07K 2319/02: containing a signal sequence
- C07K 2319/04: containing an ER retention signal such as a C-terminal HDEL motif
- C07K 2319/095: containing a nuclear export signal
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

## Claims

### Claim 1

A fusion protein comprising:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and
(c) an antigen of a pathogen, located at the C-terminus of the translocation peptide;
(d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and
(e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

### Claim 2 (depends on 1)

The fusion protein of claim 1, wherein the APC-binding domain or the CD91 receptor-binding domain is a polypeptide comprising an amino acid sequence that is at least 90% identical to the sequence selected from the group consisting of SEQ ID NOs: 1 and 8-11.

### Claim 3 (depends on 1)

The fusion protein of claim 1, wherein the nuclear export signal comprises the amino acid sequence of SEQ ID NO: 14.

### Claim 4 (depends on 1)

The fusion protein of claim 1, wherein the endoplasmic reticulum retention sequence comprises the amino acid sequence of SEQ ID NO: 15.

### Claim 5 (depends on 1)

The fusion protein of claim 1, wherein the nuclear export signal is located between the translocation peptide and the antigen.

### Claim 6 (depends on 1)

The fusion protein of claim 1, wherein the nuclear export signal is located between the antigen and the endoplasmic reticulum retention sequence.

### Claim 7 (depends on 1)

The fusion protein of claim 1, wherein the nuclear export signal and the ER retention sequence forms a fusion peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 12.

### Claim 8 (depends on 1)

The fusion protein of claim 1, wherein the translocation peptide has 34-61 amino acid residues in length.

### Claim 9 (depends on 1)

The fusion protein of claim 1, wherein the APC-binding domain or the CD91 receptor-binding domain is free of the amino acid sequence of Pseudomonas exotoxin A (PE) binding domain I.

### Claim 10 (depends on 9)

The fusion protein of claim 9, wherein the APC-binding domain or the CD91 receptor-binding domain comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 11 (depends on 1)

The fusion protein of claim 1, wherein the amino acid sequence of the APC-binding domain or the CD91 receptor-binding domain is SEQ ID NO: 1.

### Claim 12 (depends on 11)

The fusion protein of claim 11, wherein the translocation peptide has 34-61 amino acid residues in length.

### Claim 13 (depends on 12)

The fusion protein of claim 12, wherein the nuclear export signal and the ER retention sequence forms a fusion peptide with an amino acid sequence that is at least 90% identical to SEQ ID NO: 12.

### Claim 14 (depends on 11)

The fusion protein of claim 11, wherein the translocation peptide has 34-46 amino acid residues in length.

### Claim 15 (depends on 10)

The fusion protein of claim 10, wherein the translocation peptide has 34-61 amino acid residues in length.

### Claim 16 (depends on 15)

The fusion protein of claim 15, wherein the nuclear export signal and the ER retention sequence forms a fusion peptide with an amino acid sequence that is at least 90% identical to SEQ ID NO: 12.

### Claim 17 (depends on 1)

The fusion protein of claim 1, wherein the antigen is a fusion antigen of two or more antigenic peptides from a pathogen.

### Claim 18 (depends on 1)

The fusion protein of claim 1, consisting essentially of:
(a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein;
(b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and
(c) an antigen of a pathogen, located at the C-terminus of the translocation peptide;
(d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and
(e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.

### Claim 19 (depends on 1)

A vaccine composition comprising the fusion protein of claim 1 and an adjuvant.

### Claim 20 (depends on 1)

A method for inducing enhanced pathogen antigen-specific T cell responses, comprising:
administering a vaccine composition comprising a therapeutically effective amount of the fusion protein of claim 1 to a subject in need thereof, and thereby inducing enhanced pathogen antigen-specific T cell responses.
